Literature DB >> 26023062

Periappendicitis during adalimumab treatment for ileocecal Crohn's disease in a 29-year-old male.

Shinta Mizuno1, Atsushi Nakazawa, Ayumi Ogawa, Tadakazu Hisamatsu, Shigemichi Hirose, Nobuhiro Tsukada.   

Abstract

A 29-year-old male was diagnosed with ileocolic Crohn's disease (CD) approximately 2 years ago. Adalimumab was prescribed as CD remission induction therapy. Three months after beginning adalimumab, watery diarrhea and lower abdominal pain developed. He was admitted under a diagnosis of CD exacerbation. Despite fasting and antibiotic treatment, symptoms of acute panperitonitis appeared. He was diagnosed as acute appendicitis and we performed emergency surgery for peritoneal drainage and ileocecal resection on the fifth hospital day. We diagnosed periappendicitis based on the operative findings. This is the first report of periappendicitis with CD during adalimumab treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26023062     DOI: 10.1007/s12328-015-0575-x

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  10 in total

1.  Periappendicitis: Clinical reality or pathologic curiosity?

Authors:  M B O'Neil; D B Moore
Journal:  Am J Surg       Date:  1977-09       Impact factor: 2.565

2.  Periappendicitis: is it a clinical entity?

Authors:  Asish Mukherjee; Evelyn Schlenker; Teresa LaMasters; Melissa Johnson; Jamie Brunz; Eric Thomas
Journal:  Am Surg       Date:  2002-10       Impact factor: 0.688

3.  Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.

Authors:  Edoardo Savarino; Giorgia Bodini; Pietro Dulbecco; Lorenzo Assandri; Linda Bruzzone; Fabrizio Mazza; Anna Chiara Frigo; Valentina Fazio; Elisa Marabotto; Vincenzo Savarino
Journal:  Am J Gastroenterol       Date:  2013-09-10       Impact factor: 10.864

4.  Adalimumab induces deep remission in patients with Crohn's disease.

Authors:  Jean-Frédéric Colombel; Paul J Rutgeerts; William J Sandborn; Mei Yang; Anne Camez; Paul F Pollack; Roopal B Thakkar; Anne M Robinson; Naijun Chen; Parvez M Mulani; Jingdong Chao
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-12       Impact factor: 11.382

5.  Periappendicitis is a significant clinical finding.

Authors:  A S Fink; C A Kosakowski; J R Hiatt; A J Cochran
Journal:  Am J Surg       Date:  1990-06       Impact factor: 2.565

6.  Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients.

Authors:  Ali Syed; Raymond K Cross; Mark H Flasar
Journal:  Am J Gastroenterol       Date:  2013-03-12       Impact factor: 10.864

Review 7.  Have biologics changed the natural history of Crohn's disease?

Authors:  Michael D Mandel; Pal Miheller; Katalin Müllner; Petra A Golovics; Peter L Lakatos
Journal:  Dig Dis       Date:  2014-06-23       Impact factor: 2.404

Review 8.  Inflammatory bowel disease.

Authors:  Clara Abraham; Judy H Cho
Journal:  N Engl J Med       Date:  2009-11-19       Impact factor: 91.245

9.  Periappendicitis: our 13 year experience.

Authors:  Poras Chaudhary; Ishaq Nabi; Mohinder P Arora
Journal:  Int J Surg       Date:  2014-07-30       Impact factor: 6.071

10.  Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.

Authors:  Mamoru Watanabe; Toshifumi Hibi; Nael M Mostafa; Jingdong Chao; Vipin Arora; Anne Camez; Joel Petersson; Roopal Thakkar
Journal:  J Crohns Colitis       Date:  2014-05-27       Impact factor: 9.071

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.